Drug class

Antiplatelet and Antithrombotic Drugs (Selected Group 2)

The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines. Read more about Antiplatelet and Antithrombotic Drugs (Selected Group 2)

104 drugs in this class 73 manufacturers

Advertisement

Drugs in Antiplatelet and Antithrombotic Drugs (Selected Group 2)

Showing 73–81 of 104 drugs

WARFARIN SODIUM

ORAL ANTICOAGULANTS · MYOCARDIAL REINFARCTION PREVENTION ·+12
PD-RX PHARM

WARFARIN SODIUM

ORAL ANTICOAGULANTS · MYOCARDIAL REINFARCTION PREVENTION ·+12
AHP

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
SLATE/PREMIERPR

DIPYRIDAMOLE

ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · THROMBOEMBOLISM DUE TO PROSTHETIC HEART VALVES
Amneal Pharmaceuticals

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
MYLAN INST-NOVA

DIPYRIDAMOLE

ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL PERFUSION IMAGE, ADJUNCT
Hikma Pharmaceuticals USA

TICAGRELOR

ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
HISUN PHARMACEU

TICAGRELOR

ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
TEVA PHARM
Filter & compare in the drug finder → Opens the drug finder with Antiplatelet and Antithrombotic Drugs (Selected Group 2) preselected. Add indication or manufacturer filters there.

About Antiplatelet and Antithrombotic Drugs (Selected Group 2).

The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines.

Instead, it reflects an administrative, institutional, or formulary-specific grouping rather than an established physiological classification.

Broadly, antithrombotic and antiplatelet agents prevent pathologic vascular thrombosis by inhibiting platelet activation, aggregation, or components of the coagulation cascade.

Clinically, these agents are utilized to prevent and manage thromboembolic conditions, including acute coronary syndromes, ischemic stroke, transient ischemic attacks, and deep vein thrombosis.